Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4221 Assessing the frequency of type I gastric neuroendocrine neoplasms in autoimmune atrophic gastritis: A multi-center study in Italy

Introduction: In autoimmune atrophic gastritis (AAG), mucosa morpho-functional changes lead to hypo-achlorhydria, hypergastrinemia, and enterochromaffin-like (ECL) cells proliferation, escalating the risk of type I gastric neuroendocrine neoplasms (gNENs). Longitudinal studies on the AAG-gNENs association are scanty.

Conference:

Presenting Author: Gallo C

Authors: Massironi S, Gallo C, Lahner E, Sciola V, Cavalcoli F,

Keywords: neuroendocrine tumor, atrophic gastritis, autoimmune gastritis, gastrin,

#3232 Treatment outcomes of patients with G3 neuroendocrine neoplasms - Data from the German NET Registry

Introduction: NEN G3 comprise a heterogeneous group of rare aggressive neoplasm with few established treatment options.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Luecke S

Authors: Luecke S, Fottner C, Lahner H, Jann H, Zolnowski D,

Keywords: NEN G3, NEC, NET, Ki67, prognosis, chemotherapy,

#2094 Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study

Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Pavel M, Denecke T, Lahner H, Hörsch D, Rinke A,

Keywords: lanreotide, temozolomide, somatostatin analogues, combination therapy, progressive advanced NET, SONNET,

#1795 Results from a Phase 2, Open-Label, Multicenter, Randomized Study of the Novel, Octreotide (Oct) Subcutaneous (SC) Depot Formulation in Patients with Functioning Neuroendocrine Tumors (NETs) and Acromegaly Previously Treated with Long-Acting Octreotide

Introduction: Oct sc depot is a novel, ready to use formulation administered via a thin needle.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Borson-Chazot , Hörsch D, Lahner , Pivonello R,

Keywords: octreotide sc depot, NET,

#1554 Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-Study

Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Raderer M

Authors: Raderer M, Hörsch D, Lahner H, Rinke A, Denecke T,

Keywords: GEP-NET, Lanreotide, Temozolomide,